Susana Solá

Dr. Susana Solá

Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2004 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PRPaulo S Ribeiro
Paulo S Ribeiro
HCHelena Cortez-Pinto
Helena Cortez-Pinto
Susana SoláSusana Solá
Susana Solá
RCRui Castro
Rui Castro
RRRita M Ramalho
Rita M Ramalho
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges

29 April 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
Susana SoláSusana Solá
Susana Solá
ZNZhenhong Nan
Zhenhong Nan
RCRui Castro
Rui Castro
PRPaulo S. Ribeiro
Paulo S. Ribeiro
CSClifford J. Steer
Clifford J. Steer
Tauroursodeoxycholic acid (TUDCA), an endogenous bile acid, modulates cell death by interrupting classic pathways of apoptosis. Intracerebral hemorrhage (ICH) is a devastating acute neurological disorder, without effective treatment, in which a significant loss of neuronal cells is thought to occur by apoptosis. In this study, we evaluated whether TUDCA can reduce brain injury and improve neurological function after ICH in rats. Administration of TUDCA before or up to 6 h after stereotaxic collagenase injection into the striatum reduced lesion volumes at 2 days by as much as 50%. Apoptosis was ≈50% decreased in the area immediately surrounding the hematoma and was associated with a similar inhibition of caspase activity. These changes were also associated with improved neurobehavioral deficits as assessed by rotational asymmetry, limb placement, and stepping ability. Furthermore, TUDCA treatment modulated expression of certain Bcl-2 family members, as well as NF-κB activity. In addition to its protective action at the mitochondrial membrane, TUDCA also activated the Akt-1/protein kinase Bα survival pathway and induced Bad phosphorylation at Ser-136. In conclusion, reduction of brain injury underlies the wide-range neuroprotective effects of TUDCA after ICH. Thus, given its clinical safety, TUDCA may provide a potentially useful treatment in patients with hemorrhagic stroke and perhaps other acute brain injuries associated with cell death by apoptosis.

3 August 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMárcia M. Aranha
Márcia M. Aranha
DSDaniela M. Santos
Daniela M. Santos
Susana SoláSusana Solá
Susana Solá
CSClifford J. Steer
Clifford J. Steer
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
MicroRNAs (miRNAs or miRs) participate in the regulation of several biological processes, including cell differentiation. Recently, miR-34a has been implicated in the differentiation of monocyte-derived dendritic cells, human erythroleukemia cells, and mouse embryonic stem cells. In addition, members of the miR-34 family have been identified as direct p53 targets. However, the function of miR-34a in the control of the differentiation program of specific neural cell types remains largely unknown. Here, we investigated the role of miR-34a in regulating mouse neural stem (NS) cell differentiation. miR-34a overexpression increased postmitotic neurons and neurite elongation of mouse NS cells, whereas anti-miR-34a had the opposite effect. SIRT1 was identified as a target of miR-34a, which may mediate the effect of miR-34a on neurite elongation. In addition, acetylation of p53 (Lys 379) and p53-DNA binding activity were increased and cell death unchanged after miR-34a overexpression, thus reinforcing the role of p53 during neural differentiation. Interestingly, in conditions where SIRT1 was activated by pharmacologic treatment with resveratrol, miR-34a promoted astrocytic differentiation, through a SIRT1-independent mechanism. Our results provide new insight into the molecular mechanisms by which miR-34a modulates neural differentiation, suggesting that miR-34a is required for proper neuronal differentiation, in part, by targeting SIRT1 and modulating p53 activity.

1 May 2002 in Hepatology
Verified
Journal Article
Closed access
PDF file
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
Susana SoláSusana Solá
Susana Solá
Dora BritesDora Brites
Dora Brites
Increased levels of unconjugated bilirubin, the end-product of heme catabolism, are detrimental to the central nervous system. To examine the role of apoptosis in bilirubin-induced toxicity and to characterize the biochemical pathway of cell death, we exposed developing rat brain neurons to purified unconjugated bilirubin at concentrations below and above saturation of human serum albumin. Isolated neurons treated with bilirubin showed increased levels of apoptosis. Mitochondrial cytochrome c was extensively released and accumulated in cytosol. Consistent with this observation, caspase-3 was activated and the full-length substrate poly(ADP)ribose polymerase (PARP) degraded, even in the presence of very modestly elevated concentrations of bilirubin. In parallel, all events were prevented in cells preincubated with ursodeoxycholate. Further experiments showed that bilirubin diminished mitochondrial transmembrane potential (ΔΨm) and increased mitochondrial-associated Bax protein levels, while directly disrupting membrane lipid and protein structure. In conclusion, bilirubin induces mitochondrial depolarization and Bax translocation via physical interaction with membranes, mediating the mitochondrial pathway of apoptosis in neurons exposed to bilirubin. These results provide a novel insight into the mechanism of bilirubin-induced toxicity.

1 April 2002 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
SSStephen R. Spellman
Stephen R. Spellman
Susana SoláSusana Solá
Susana Solá
AGAndrew W. Grande
Andrew W. Grande
CLCheryle Linehan-Stieers
Cheryle Linehan-Stieers
CSClifford J. Steer
Clifford J. Steer
Tauroursodeoxycholic acid (TUDCA), a hydrophilic bile acid, is a strong modulator of apoptosis in both hepatic and nonhepatic cells, and appears to function by inhibiting mitochondrial membrane perturbation. Excitotoxicity, metabolic compromise, and oxidative stress are major determinants of cell death after brain ischemia-reperfusion injury. However, some neurons undergo delayed cell death that is characteristic of apoptosis. Therefore, the authors examined whether TUDCA could reduce the injury associated with acute stroke in a well-characterized model of transient focal cerebral ischemia. Their model of middle cerebral artery occlusion resulted in marked cell death with prominent terminal deoxynucleotidyl transferase-mediated 2′-deoxyuridine 5′-triphosphate-biotin nick end labeling (TUNEL) within the ischemic penumbra, mitochondrial swelling, and caspase activation. Tauroursodeoxycholic acid administered 1 hour after ischemia resulted in significantly increased bile acid levels in the brain, improved neurologic function, and an approximately 50% reduction in infarct size 2 and 7 days after reperfusion. In addition, TUDCA significantly reduced the number of TUNEL-positive brain cells, mitochondrial swelling, and partially inhibited caspase-3 processing and substrate cleavage. These findings suggest that the mechanism for in vivo neuroprotection by TUDCA is, in part, mediated by inhibition of mitochondrial perturbation and subsequent caspase activation leading to apoptotic cell death. Thus, TUDCA, a clinically safe molecule, may be useful in the treatment of stroke and possibly other apoptosis-associated acute and chronic injuries to the brain.

20 February 2003 in Biochemistry
Verified
Journal Article
Closed access
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
Susana SoláSusana Solá
Susana Solá
JSJuanita C. Sharpe
Juanita C. Sharpe
Jose J. G. MouraJose J. G. Moura
Jose J. G. Moura
CSClifford J. Steer
Clifford J. Steer